These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 35211412)

  • 1. Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.
    Cerchione C; Usmani SZ; Stewart AK; Kaiser M; Rasche L; Kortüm M; Mateos MV; Spencer A; Sonneveld P; Anderson KC
    Front Oncol; 2022; 12():820768. PubMed ID: 35211412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling as a prognostic tool in multiple myeloma.
    Black H; Glavey S
    Cancer Drug Resist; 2021; 4(4):1008-1018. PubMed ID: 35582380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial.
    Biran N; Dhakal B; Lentzsch S; Siegel D; Usmani SZ; Rossi A; Rosenbaum C; Bhutani D; Vesole DH; Rodriguez C; Nooka AK; van Rhee F; Stork-Sloots L; de Snoo F; Bhattacharyya PK; Dash DP; Zümrütçü S; van Vliet MH; Hari P; Niesvizky R
    EJHaem; 2021 Aug; 2(3):375-384. PubMed ID: 35844693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial.
    Hose D; Beck S; Salwender H; Emde M; Bertsch U; Kunz C; Scheid C; Hänel M; Weisel K; Hielscher T; Raab MS; Goldschmidt H; Jauch A; Moreaux J; Seckinger A
    J Hematol Oncol; 2019 Jun; 12(1):65. PubMed ID: 31242924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic gene expression analysis in a retrospective, multinational cohort of 155 multiple myeloma patients treated outside clinical trials.
    Chen YT; Valent ET; van Beers EH; Kuiper R; Oliva S; Haferlach T; Chng WJ; van Vliet MH; Sonneveld P; Larocca A
    Int J Lab Hematol; 2022 Feb; 44(1):127-134. PubMed ID: 34448362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in biology and therapy of multiple myeloma.
    Barillé-Nion S; Barlogie B; Bataille R; Bergsagel PL; Epstein J; Fenton RG; Jacobson J; Kuehl WM; Shaughnessy J; Tricot G
    Hematology Am Soc Hematol Educ Program; 2003; ():248-78. PubMed ID: 14633785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
    Hose D; Rème T; Hielscher T; Moreaux J; Messner T; Seckinger A; Benner A; Shaughnessy JD; Barlogie B; Zhou Y; Hillengass J; Bertsch U; Neben K; Möhler T; Rossi JF; Jauch A; Klein B; Goldschmidt H
    Haematologica; 2011 Jan; 96(1):87-95. PubMed ID: 20884712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
    Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
    Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.
    Hose D; Seckinger A; Jauch A; Rème T; Moreaux J; Bertsch U; Neben K; Klein B; Goldschmidt H
    Srp Arh Celok Lek; 2011 Dec; 139 Suppl 2():84-9. PubMed ID: 22352188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.
    Johnson SK; Heuck CJ; Albino AP; Qu P; Zhang Q; Barlogie B; Shaughnessy JD
    Int J Hematol; 2011 Oct; 94(4):321-333. PubMed ID: 22002477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma: is it time for biomarker-driven therapy?
    Bhutani M; Landgren O; Usmani SZ
    Am Soc Clin Oncol Educ Book; 2015; ():e493-503. PubMed ID: 25993214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma.
    Kryukov F; Nemec P; Radova L; Kryukova E; Okubote S; Minarik J; Stefanikova Z; Pour L; Hajek R
    J Transl Med; 2016 May; 14(1):150. PubMed ID: 27234807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Immune-Related Genes for Risk Stratification in Multiple Myeloma Based on Whole Bone Marrow Gene Expression Profiling.
    Wang QS; Shi QQ; Meng Y; Chen MP; Hou J
    Front Genet; 2022; 13():897886. PubMed ID: 35692836
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple myeloma.
    Harousseau JL; Shaughnessy J; Richardson P
    Hematology Am Soc Hematol Educ Program; 2004; ():237-56. PubMed ID: 15561686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic markers used for risk stratification in multiple myeloma.
    Segges P; Braggio E
    Genet Res Int; 2011; 2011():798089. PubMed ID: 22567368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical Validation of SKY92 for the Identification of High-Risk Multiple Myeloma.
    van Beers EH; Huigh D; Bosman L; de Best L; Kuiper R; Spaan M; van Duin M; Sonneveld P; Dumee B; van Vliet MH
    J Mol Diagn; 2021 Jan; 23(1):120-129. PubMed ID: 33152501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma.
    Lê GN; Bones J; Coyne M; Bazou D; Dowling P; O'Gorman P; Larkin AM
    Mol Omics; 2019 Feb; 15(1):7-20. PubMed ID: 30652172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells.
    Meißner T; Seckinger A; Hemminki K; Bertsch U; Foersti A; Haenel M; Duering J; Salwender H; Goldschmidt H; Morgan GJ; Hose D; Weinhold N
    BMC Med Genomics; 2015 Dec; 8():85. PubMed ID: 26714877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies.
    Kazandjian D; Mailankody S; Korde N; Landgren O
    Clin Adv Hematol Oncol; 2014 Sep; 12(9):578-87. PubMed ID: 25654479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.